跳至主要内容
临床试验/NCT06082674
NCT06082674已完成2 期

Novel Low Cost Bubble CPAP as an Alternative Non-invasive Respiratory Support Among Preterm Infants With Respiratory Distress Syndrome

Ilocos Training and Regional Medical Center1 个研究点 分布在 1 个国家目标入组 70 人开始时间: 2022年4月1日最近更新:
适应症
干预措施

试验速览

阶段
2 期
状态
已完成
入组人数
70
试验地点
1
主要终点
Partial pressure of carbon dioxide (pC02) using Arterial Blood Gas

研究概览

简要总结

This is a single-blind randomized controlled trial done in a Level III neonatal intensive care unit. Preterm newborns with RDS were randomized to receive oxygen therapy through bubble CPAP vs ventilator-derived CPAP. Differences in arterial blood gases, oxygen saturation, number of surfactant and CPAP failure rate between study groups were analyzed.

详细描述

Background and Objective: Respiratory distress syndrome (RDS) among premature infants is one of the major causes of neonatal death. The use of continuous positive airway pressure (CPAP) has become a standard of care for preterm newborns with RDS. In countries faced with the challenge of improving neonatal care, cost-effective innovations for respiratory support are a promising intervention. This study determined the efficacy of a low-cost bubble CPAP as an alternative non-invasive oxygen therapy for newborn infants with RDS.

METHODS: This is a single-blind randomized controlled trial done in a Level III neonatal intensive care unit. Preterm newborns with RDS were randomized to receive oxygen therapy through bubble CPAP vs ventilator-derived CPAP. Differences in arterial blood gases, oxygen saturation, number of surfactant and CPAP failure rate between study groups were analyzed.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Investigator, Outcomes Assessor)

盲法说明

The study Blinded the investigator and outcome assesors

入排标准

年龄范围
5 Minutes 至 6 Hours(Child)
性别
All
接受健康志愿者
否

入选标准

  • •Included are preterm neonates less than 36 weeks (WHO definition)
  • •admitted at NICU
  • •APGAR scores of > 7 in the 1st and 5th minute of life
  • •in respiratory distress at birth,
  • •radiologic findings of RDS
  • •Respiratory Severity Score (RSS) or Downe's score > 4 at 10-15 minutes after hooking to CPAP
  • •requiring CPAP or more than 40% FiO2

排除标准

  • •Infants requiring neonatal resuscitation such as bag mask ventilation, chest compression or intubation at birth
  • •with comorbidities such as facial anomalies, tracheoesophageal fistulas, congenital heart disease, and other congenital anomalies which may interfere with the interface of both devices.

研究组 & 干预措施

Vayu CPAP Group

Experimental

The patients will be hooked to VAYu bCPAP

干预措施: Vayu bCPAP (Device)

Mechanical Ventilator Driven CPAP

Active Comparator

Patients will be hooked to Mechanical Ventilator Driven CPAP

干预措施: Mechanical Ventilator Driven CPAP (Device)

结局指标

主要结局

Partial pressure of carbon dioxide (pC02) using Arterial Blood Gas

时间窗: 8 months

Difference in the Partial pressure of carbon dioxide (pC02) using Arterial Blood Gas

Oxygen Saturation

时间窗: 8 months

Difference in the oxygen saturation using pulse oximeter

Partial pressure of arterial oxygen (pa02) using Arterial Blood Gas

时间窗: 8 months

Difference in the Partial pressure of arterial oxygen (pa02) using Arterial Blood Gas

次要结局

  • CPAP Failure(8 months)
  • surfactant use(8 months)

研究者

申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Navid Roodaki

Dr.

Ilocos Training and Regional Medical Center

研究点 (1)

Loading locations...

相似试验

进行中(未招募)
1 期
A clinical research study to test the safety, tolerability and effectiveness of the investigational vaccine to prevent shingles in individuals with weak immune system such as people with cancer.Incidence of Herpes Zoster in adults with solid tumor or hematologic malignancyMedDRA version: 18.1Level: PTClassification code 10019974Term: Herpes zosterSystem Organ Class: 10021881 - Infections and infestations
EUCTR2010-023156-89-LTMerck Sharp & Dohme Corp., a Subsidiary of Merck & Co, Inc.5,136
进行中(未招募)
1 期
A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic MalignancyIncidence of Herpes Zoster in adults with solid tumorMedDRA version: 18.1Level: PTClassification code 10019974Term: Herpes zosterSystem Organ Class: 10021881 - Infections and infestations
EUCTR2010-023156-89-ATMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.5,264
招募中
不适用
A Phase III Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy
KCT0000393MSD Korea5,264
进行中(未招募)
1 期
ot availableIncidence of Herpes Zoster in adults with solid tumor or hematologic malignancyMedDRA version: 18.1Level: PTClassification code 10019974Term: Herpes zosterSystem Organ Class: 10021881 - Infections and infestations
EUCTR2010-023156-89-EEMerck Sharp & Dohme Corp., a Subsidiary of Merck & Co, Inc.5,264
Unknown
3 期
Randomized, double-blind, placebo-controled stdy to assess the safety &tolerability of V212 when administered to adults with solid tumor malignancy (STM) or hematologic malignancy (HM)& determine whether V212 reduces the incidence of herpes zoster (HZ) in adults with STM or HM as compared to placebo
CTRI/2012/05/002673Merck Sharp and Dohme5,264